A new study published in the American Heart Association’s Circulation medical journal suggests that novel blood-thinners Xarelto and Pradaxa are not any safer than competitor drug warfarin. Researchers from the National Health Insurance Strategy and Research Department in France focused on the early effects the anticoagulants had on over 32,000 patients, noting that there was “no statically significant difference in bleeding or thromboembolic risk” observed in the first 90 days among patients taking novel blood-thinners Xarelto or Pradaxa versus those taking vitamin K antagonists such as warfarin.
Due to their lack of a blood monitoring protocol or reversal agent to stop life-threatening bleeding, Xarelto and Pradaxa have come under fire recently. Mounting complaints on behalf of individuals throughout the United States alleged that the manufacturer of Xarelto and the manufacturer of Pradaxa have misleadingly marketed their drugs as not requiring blood monitoring and downplaying severe bleeding risks. Hundreds of lawsuits have been filed against the makers of these drugs, particularly Xarelto’s co-sponsors Bayer Healthcare and Johnson & Johnson. Many of those plaintiffs are being represented by Grant & Eisenhofer, a law firm involved in the Bellwether Selection Committee and leading the Law & Briefing Committee of the Xarelto multi-district litigation, or MDL.